ClinicalTrials.gg
RecruitingNCT05922644SCS-ICHUpdated Jul 3, 2023

Short-term Cervical Spinal Cord Stimulation in Patients With Disorders of Consciousness After Intracerebral Hemorrhage

An interventional study of SCS and Conventional in Coma and Stroke, sponsored by Beijing Tiantan Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-07-03.

Sponsored by Beijing Tiantan Hospital · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
344
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Coma with a site in China — 4 open to participants now, 4 under way, none of them phase 3. Coma · China.

Started
2023
the only one that year
No phase
7 of 10
3 open now
Registered
6th of 10
by date
Lead sponsor
1 of 10
Beijing Tiantan Hospital

Among the 10 studies in Coma with a site in China, this one is the only one that started in 2023, is one of 7 with no phase, and was the 6th registered.

Coma

138 studies on the registry are indexed under Coma; 34 are open to participants now.

Browse Coma studies →

Open to participants now

4 of the 10 studies in Coma with a site in China are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 22 Coma studies recruiting now, 14 (64%) set no upper age limit and 4 (18%) stop at 75 or younger; 5 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Coma with a site in China, or all of them as a file.
02

Study summary

Disorders of consciousness (DOC) refers to the persistent loss of consciousness after 28 days in patients with brain injury caused by trauma, stroke, or hypoxia. It includes coma, vegetative state, and minimally conscious state. At present, there is no effective treatment for DOC. Only one RCT study of amantadine has proved that it may be effective for the treatment of DOC. In recent years, more evidence has shown that neuromodulation technology is beneficial to the recovery of DOC. Cervical spinal cord stimulation surgery is a new treatment method for patients with DOC. Electrodes are implanted in the high cervical spinal cord C2-C5. By adjusting different electrical stimulation parameters, it has a wake-promoting effect. In this study, patients were selected into the spinal cord stimulation group and the conventional treatment group according to the wishes of their families. The patients in the spinal cord stimulation group were given 21 days of cervical spinal cord stimulation treatment on the basis of conventional brain rehabilitation. Patients were followed up routinely and completed designated examinations at 12 months to determine the safety and efficacy of cervical spinal cord stimulation therapy.

03

Conditions studied

  • Coma
  • Stroke

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 65 years old
  • Patients with postoperative consciousness disorders after cerebral hemorrhage for more than 28 days
  • CRS-R score meets the MCS diagnosis
  • Signed .

Exclusion criteria

Exclusion Criteria:

  • Secondary brain injury caused by arteriovenous malformation, cerebral aneurysm, cavernous hemangioma, brain tumor and carbon monoxide poisoning
  • History of previous epileptic seizures
  • Critical condition, unstable intracranial condition, risk of rebleeding
  • Unstable vital signs requiring mechanical ventilation
  • for spinal cord surgery
  • Severe sympathetic overactivity syndrome.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
344 participants (estimated)

Study arms

  • Experimental
    Spinal cord electrical stimulation group

    According to the EDC system, patients are randomly assigned to receive 21 days of cervical spinal cord electrical stimulation treatment in addition to routine brain resuscitation and rehabilitation awakening treatment.

    Device: SCS

  • Sham comparator
    Conventional treatment group

    According to the EDC system, patients are randomly assigned to receive only routine brain resuscitation and rehabilitation awakening treatment.

    Other: Conventional

Interventions

  • DeviceSCS

    21 days of cervical spinal cord electrical stimulation treatment in addition to routine brain resuscitation and rehabilitation awakening treatment.

  • OtherConventional

    Routine brain resuscitation and rehabilitation awakening treatment.

06

What researchers measure

Primary outcomes

  1. Change in consciousness 12 months after surgery assessed by CRS-R

    The primary efficacy indicator is "change in consciousness recovery 12 months after cervical spinal cord electrical stimulation (assessed by the Coma Recovery Scale - Revised (CRS-R), ranges from 0 to 25, with higher scores mean a better outcome)".

    Time frame: 12 months

Secondary outcomes

  1. Consciousness recovery 12 months after surgery assessed by GOS-E

    The secondary efficacy indicator is "consciousness recovery 12 months after surgery (assessed by the Glasgow Outcome Scale - Extended (GOS-E) to evaluate the patient's consciousness status, ranges from 0 to 8, with higher scores mean a better outcome)".

    Time frame: 12 months

Other outcomes

  1. Glasgow Coma Scale (GCS)

    Exploratory Indicators, ranges from 0 to 15, with higher scores mean a better outcome.

    Time frame: 12 months

  2. National Institute of Health stroke scale (NIHSS)

    Exploratory Indicators, ranges from 0 to 42, with higher scores mean a worse outcome.

    Time frame: 12 months

  3. Full Outline of UnResponsiveness (FOUR) Score

    Exploratory Indicators, ranges from 0 to 16, with higher scores mean a better outcome.

    Time frame: 12 months

  4. Disability rating scale (DRS)

    Exploratory Indicators, ranges from 0 to 29, with higher scores mean a worse outcome.

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2023; primary completion for Sep 2026, 38 months later.

Of 39 non-industry interventional studies with no phase under Coma, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 54. This study's planned 38 months is close to that.

Counting every sponsor, half of 39 studies reached it within 39 months; a quarter within 17 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2023
First posted
Jun 28, 2023
StartEst.
Jul 1, 2023
Primary completionEst.
Sep 1, 2026
CompletionEst.
Sep 1, 2030
Last update
Jul 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05922644
Collaborators
Rehabilitation Hospital Affiliated to National Research Center for Rehabilitation Technical Aids, Shenzhen Qianhai Shekou Free Trade Zone Hospital
Responsible party
Dr. Yong Cao (director, Beijing Tiantan Hospital) — Principal investigator
First posted
Jun 28, 2023
Start date
Jul 1, 2023 (estimated)
Primary completion
Sep 1, 2026 (estimated)
Completion
Sep 1, 2030 (estimated)
Last update
Jul 3, 2023

Study contacts

Yong Cao, MD
Contact
caoyong@bjtth.org
+8613601362306
Qiheng He, MD
Contact
heqiheng96@mail.ccmu.edu.cn
+8615699952258

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion